AEVI GENOMIC MEDICINE, INC. (LON:MEDG) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On April 24, 2017, Isaac Blech informed Aevi Genomic Medicine, Inc. (the “Company”) that he intends to retire from the Company’s Board of Directors upon the expiration of his current term at the Company’s 2017 annual meeting of stockholders (the “2017 Annual Meeting”). As a result of Mr. Blech’s planned retirement, he will not stand for election at the 2017 Annual Meeting. Mr. Blech has been a member of the Board of Directors for almost six years. The Company thanks him for his service and commitment to the Company.

About AEVI GENOMIC MEDICINE, INC. (LON:MEDG)

Aevi Genomic Medicine, Inc., formerly Medgenics, Inc., is focused on genomic medicine. The Company is engaged in unlocking the potential of genomic medicine to translate genetic discoveries into therapies. The Company is engaged in developing therapies for children and adults with pediatric onset life altering diseases. The Company’s product candidates include AEVI-001 and AEVI-002. The Company’s research and development efforts leverage an internal genomics platform and a collaboration with the Center for Applied Genomics (CAG) at The Children’s Hospital of Philadelphia (CHOP). .

AEVI GENOMIC MEDICINE, INC. (LON:MEDG) Recent Trading Information

AEVI GENOMIC MEDICINE, INC. (LON:MEDG) closed its last trading session at 0.0000 with shares trading hands.